Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Notes Payables (2016 - 2023)

Fortress Biotech (FBIO) has 10 years of Notes Payables data on record, last reported at $3.0 million in Q1 2023.

  • For Q1 2023, Notes Payables changed N/A year-over-year to $3.0 million; the TTM value through Mar 2023 reached $3.0 million, changed N/A, while the annual FY2022 figure was $2.9 million, 263.05% up from the prior year.
  • Notes Payables reached $3.0 million in Q1 2023 per FBIO's latest filing, up from $2.9 million in the prior quarter.
  • Across five years, Notes Payables topped out at $85.4 million in Q1 2020 and bottomed at $812000.0 in Q4 2021.
  • Average Notes Payables over 5 years is $30.4 million, with a median of $9.9 million recorded in 2019.
  • Peak YoY movement for Notes Payables: soared 688.35% in 2019, then plummeted 93.6% in 2021.
  • A 5-year view of Notes Payables shows it stood at $7.2 million in 2019, then skyrocketed by 611.81% to $51.4 million in 2020, then crashed by 98.42% to $812000.0 in 2021, then skyrocketed by 263.05% to $2.9 million in 2022, then increased by 1.76% to $3.0 million in 2023.
  • Per Business Quant database, its latest 3 readings for Notes Payables were $3.0 million in Q1 2023, $2.9 million in Q4 2022, and $812000.0 in Q4 2021.